Exercise Training
BehavioralThree times a week, for four months.
NCT Number: NCT01931540
The prevalence of obesity in the developed world has increased markedly over the last 20 years. Considering the prevalence of obese and overweight adult subjects, and the fact that pregnancy itself induces a state of insulin resistance and inflammation, maternal obesity may be the most common health risk for the developing fetus. It is well established that what we eat has a major impact on our health. However, there is growing evidence to suggest that diet during pregnancy and lactation may be particularly important as not only does it influence the health of the mother, it may have a permanent effect on the health of her children and even her grandchildren. The concept that environmental factors, such as nutrition during early development, influence both our health span and lifespan has been termed the developmental origins of health and disease hypothesis.
The objective of the study are:
* to compare subjects with frailty (condition developed with ageing) with controls and characterize the unhealthy aged condition with the measurements described below * to examine if signs of frailty can be reversed by lifestyle induced modifications (exercise training programme) of its primary components (IR, sarcopenia, psychological profile) in offspring of overweight/obese (OOM) vs lean mothers (OLM).
The study consists of 37 frail old subjects, age ≥ 65 sub-grouped in 17 OOM, and 20 OLM and 11 non frail controls. These subjects will be studied with positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI) and spectroscopy (MRS) and ultra sounds (US). In addition functional MRI (fMRI) will be performed. Adipose tissue biopsies will be taken.
Subjects will undergo characterization of biohumoral markers, a 75 g oral glucose tolerance test, imaging biomarkers (PET/CT, US, fMRI-MRS), genetic biomarkers (DNA and telomere damage) and inflammatory biomarkers (macrophage infiltration) before and after the 4-month lifestyle intervention period (physical exercise). By PET/CT it will be measured tissue-specific IR in skeletal muscle, adipose tissue, liver, myocardium and targeted brain regions. MRS will be used to measure organ steatosis in the skeletal muscle and liver, MRI will be used to measure fat masses in abdominal areas, and fMRI will be performed to assess activation in brain regions regulating cognition and appetite/energy control. US will be used to assess cardiovascular markers (IMT, strain and function).
Looking for future studies?
Notify MeFemale
Interventional
Not applicable
University of Helsinki, Department of General Practice and Primary Health Care, Helsinki, Finland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Frailty Groups Inclusion Criteria:
Control group Inclusion Criteria:
Exclusion criteria
Three times a week, for four months.
Time frame: At day 1 and after 4 months of intervention (for the 15 controls only at baseline)
Assessed via 18F-Fluorodeoxyglucose (FDG)-PET/CT+Clamp technique
Time frame: At day 1 and after 4 months of intervention (for the 15 controls only at baseline)
Telomere length, H2A.X phosphorilation, mtDNA deletion are measurements performed in Pisa, National Research Council p66 presence is measured in Rome, Istituto Superiore di Sanita'
Time frame: At day 1 and after 4 months of intervention (for the 15 controls only at baseline)
Adipose tissue fat masses in different depots (subcutaneous, visceral, pericardial) Liver, skeletal muscle, vertebral fat content
Time frame: At day 1 and after 4 months of intervention
MRI anatomy: White matter volume, Cortex thickness, Nerve tracks found with Diffusor Tension Imaging fMRI will be used to identify different brain regions activated by food stimuli while subjects perform three different task: watch the food, think of eating the food, control the urge to eat the food.
Turku University Hospital
Other Gov
Acronym: DORIAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06288126
Glucose Metabolism Disorders, Hyperinsulinism
Pisa, Italy
View Trial DetailsNCT06480916
Maternal-Fetal Relations
Briey, France
View Trial DetailsNCT07268014
Birth, First, Female Urogenital Diseases
Konya, Turkey (Türkiye)
View Trial DetailsNCT06892665
Cardiovascular Diseases, Cesarean Section Complications
Cheras, Kuala Lumpur, Malaysia
View Trial Details